Lexicon Pharmaceuticals shares surge 10.24% after hours as Citi upgrades outlook citing Novo Nordisk partnership milestones.

Lexicon Pharmaceuticals surged 10.24% in after-hours trading following a successful End-of-Phase 2 meeting with the FDA for pilavapadin in treating diabetic peripheral neuropathic pain, as reported by GlobeNewswire. Additionally, Citi raised its outlook on the stock, citing milestones in Lexicon’s partnership with Novo Nordisk, as noted by Insider Monkey. These developments reinforced investor confidence in the company’s pipeline advancements and strategic collaborations, driving the significant after-hours gain.